IRE ablation with immunotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks back at people with advanced pancreatic cancer who received a treatment called IRE (a special type of ablation) along with immunotherapy. The goal is to see how well this combination works and how safe it is for patients whose cancer cannot be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced pancreatic cancer that cannot be surgically removed.
- You have already been treated with a special procedure called IRE (irreversible electroporation), either alone or together with an immunotherapy drug (like Keytruda or Tecentriq).
- You are 18 years old or older and your daily activity level is fairly good (ECOG score 0-2, meaning you can take care of yourself).
- You have complete medical records and at least 6 months of follow-up data available.
- You do not have other cancers, severe immune system disorders, or serious organ problems that would prevent further treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combining tumor destruction with heat/cold (ablation) and an immunotherapy drug (PD-1) for people whose pancreatic cancer has spread to the liver. The goal is to help the immune system fight the cancer better.
This is a research registry that collects information from adults with pancreatic cancer who are treated with an ablation procedure called irreversible electroporation (IRE). It may help doctors better understand which patients benefit from this approach and how the treatment is used in real life.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a combination of radiation therapy (SBRT), two immunotherapy drugs (Ipilimumab and Sintilimab), and two chemotherapy drugs (Nab-Paclitaxel and Gemcitabine) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this treatment can control the cancer better than standard options.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.